Urinary cyclic GMP excretion and blood pressure levels in a general population


      Dysfunction of the nitric oxide (NO) system is potentially involved in the development of hypertension, but only limited data are currently available from experimental or clinical studies. We investigated cross-sectionally the relation between urinary excretion of cyclic guanosine 3′,5′-monophosphate (cyclic GMP), a second messenger of NO, and hypertension in a general population sample of Japanese men and women. The samples comprised 1541 subjects (788 men and 753 women) aged 40–79 years who participated in cardiovascular risk surveys between 1997 and 2002 and underwent a 24 h urine collection. Urinary excretion of cyclic GMP was measured using a Math Eq-labeled cyclic GMP radioimmunoassay, and was adjusted for urinary creatinine excretion (nmol/mmol creatinine). Urinary cyclic GMP excretion was 66.0±62.0 nmol/mmol creatinine (mean±S.D.). Compared with normal blood pressure individuals, the multivariate-adjusted mean value of urinary cyclic GMP excretion was significantly higher in people with moderate hypertension, but not higher in severe hypertension. Among subjects with hypertensive end-organ damage, we observed reduced urinary cyclic GMP excretion in severe hypertension and no increased excretion in moderate hypertension, compared with normal blood pressure. Although we had the limited number of subjects with severe hypertension (n=15), our data suggest that NO bioactivity may be increase in the early stage of hypertension but decreased in severe hypertension with end-organ damage.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Furchgott R.F.
        • Zawadzki J.V.
        The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.
        Nature. 1980; 288: 373-376
        • Furchgott R.F.
        Role of endothelium in responses of vascular smooth muscle.
        Circ. Res. 1983; 53: 557-573
        • Myers P.R.
        • Minor Jr., R.L.
        • Guerra Jr., G.
        • Bates J.N.
        • Harrison D.G.
        Vasorelaxant properties of the endothelium-derived relaxing factor more closely resembles S-nitrosocystein than nitric oxide.
        Nature. 1990; 345: 161-163
        • Palmar R.M.J.
        • Ferrige A.G.
        • Moncada S.
        Nitric oxide release accounts the biological activity of endothelium-derived relaxing factor.
        Nature. 1987; 327: 524-526
        • Forstermann U.
        • Closs E.I.
        • Pollock J.S.
        • Nakane M.
        • Schwarz P.
        • Gath I.
        • et al.
        Nitric oxide synthase isoenzymes: characterization, purification, molecular cloning, and function.
        Hypertension. 1994; 23: 1121-1131
        • Moncada S.
        • Higgs A.
        The l-arginine–nitric oxide pathway.
        N. Engl. J. Med. 1993; 329: 2002-2012
        • Murad F.
        Cyclic GMP: synthesis, metabolism and function. Introduction and some historical comments.
        Adv. Pharmacol. 1994; 26: 1-5
        • Linder L.
        • Kiowski W.
        • Buhler F.R.
        • Luscher T.F.
        Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. blunted response in essential hypertension.
        Circulation. 1990; 81: 1762-1767
        • Panza J.A.
        • Casino P.R.
        • Kilcoyne C.M.
        • Quyyumi A.A.
        Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patents with essential hypertension.
        Circulation. 1993; 87: 1468-1474
      1. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patents with essential hypertension. N Eng J Med 1990;323:22–27.

        • Markovitz J.H.
        • Lewis C.E.
        • Sanders P.W.
        • Tucker D.
        • Warnock D.G.
        Relationship of diastolic blood pressure with cyclic GMP excretion among young adults (the CARDIA study): influence of a family history of hypertension. Coronary artery risk development in young adults.
        J. Hypertens. 1997; 15: 955-962
        • Wencker M.
        • Hauptlorenz S.
        • Moll W.
        • Puschendorf B.
        Influence of blood pressure, heart rate, age, and sex on concentrations of atrial natriuretic factor and cyclic GMP in 124 volunteers.
        Clin. Chem. 1989; 35: 1519-1523
        • Higashi Y.
        • Oshima T.
        • Sasaki S.
        • Nakano Y.
        • Kambe M.
        • Matsuura H.
        • et al.
        Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculature to l-arginine in patients with essential hypertension.
        Hypertension. 1998; 32: 16-24
        • Taddei S.
        • Virdis A.
        • Ghiadoni L.
        • Magagna A.
        • Favilla S.
        • Pompella A.
        • et al.
        Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension.
        Hypertension. 2001; 37: 943-948
        • Ratnam S.
        • Mookerjea S.
        The regulation of superoxide generation and nitric oxide synthesis by C-reactive protein.
        Immunology. 1998; 94: 560-568
        • Kirkendall W.M.
        • Feinleib M.
        • Freis E.D.
        • Mark A.L.
        Recommendations for human blood pressure determination by sphygmomanometers: Subcommittee of the AHA Postgraduate Education Committee.
        Circulation. 1980; 62: 1146A-1155A
      2. Hollenberg NK. Summary of the Joint National Committee (JNC)-V and WHO/International Society of Hypertension (ISH) special reports. In: Hollenberg NK, Braunwald E, editors. Hypertension: mechanisms and therapy, in atlas of heart disease, vol. 1. Philadelphia: Current Medicine; 1995. p. 13.1–16.

        • Scheie H.G.
        Evaluation of ophthalmoscopic changes of hypertension and arteriosclerosis.
        Arch. Ophthalmol. 1953; 49: 117-138
      3. Rose GA, Blackburn H. Cardiovascular survey methods. Geneva, Switzerland: World Health Organization; 1968.

        • Iso H.
        • Kitamura A.
        • Shimamoto T.
        • Sankai T.
        • Naito Y.
        • Sato S.
        • et al.
        Alcohol intake and the risk of cardiovascular disease in middle-aged Japanese men.
        Stroke. 1995; 26: 767-773
        • Iso H.
        • Naito Y.
        • Sato S.
        • Kitamura A.
        • Okamura T.
        • Sankai T.
        • et al.
        Serum triglycerides and risk of coronary heart disease among Japanese men and women.
        Am. J. Epidemiol. 2001; 153: 490-499
        • Böger R.H.
        • Bode-Böger S.M.
        • Thiele W.
        • Junker W.
        • Alexander K.
        • Frolich J.C.
        Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease.
        Circulation. 1997; 95: 2068-2074
        • Ishii T.
        • Otsuka Y.
        • Okabe T.
        • Kanmatsuse K.
        The role of nitric oxide in deoxycorticosterone acetate-salt hypertensive rats.
        Jpn. J. Nephrol. 1999; 41 (In Japanese): 43-48
        • Pohl U.
        • Holtz J.
        • Busse R.
        • Bussenge E.
        Crucial role of endothelium in the vasodilator response to increased flow in vivo.
        Hypertension. 1986; 8: 37-44
        • Rubanyi G.M.
        • Romero J.C.
        • Vanhoutte P.M.
        Flow-induced release of endothelium-derived relaxing factor.
        Am. J. Physiol. 1986; 250: H1145-H1149
        • Itoh H.
        • Sagawa N.
        • Nanno H.
        • Mori T.
        • Mukoyama M.
        • Itoh H.
        • et al.
        Impaired guanosine 3′,5′-cyclic phosphate production in severe pregnancy-induced hypertension with high plasma levels of atrial and brain natriuretic peptides.
        Endocr. J. 1997; 44: 389-393
        • Sato K.
        • Kinoshita M.
        • Kojima M.
        • Miyagawa K.
        • Takase H.
        • Suzuki S.
        • et al.
        Failure of l-arginine to induce hypotension in patients with a history of accelerated-malignant hypertension.
        J. Hum. Hypertens. 2000; 14: 485-488